Key Record Dates
| ClinicalTrials.gov Identifier: | NCT02305186 |
|---|---|
| Brief Title: | Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer (UVA-PC-PD101) |
| First Submitted : | November 21, 2014 |
| First Submitted that Met QC Criteria : | November 27, 2014 |
| First Posted : | December 2, 2014 (Estimate) |
| Last Update Submitted that Met QC Criteria : | August 11, 2021 |
| Last Update Posted : | August 13, 2021 |